European Neuropsychopharmacology (v.15, #S1)
P.3.06 A glycogen synthase kinase 3-ß -50 T/CSNP influences long-term response to lithium salts in bipolar illness by A. Pontiggia; A. Bemasconi; E. Benedetti; A. Serretti; C. Lorenzi; C. Colombo; E. Smeraldi (S56-S57).
P.3.07 Antipsychotic agents and neuromusculardysfunction by I. Reznik; L. Volchek; M. Reznik; A. Weizman; H.Y. Meltzer (S57-S58).
P.3.05 Association and haplotype analaysis of90 single-nucleotide polymorphisms in mood disorders by E. Maron; S. Kõks; T. Nikopensius; S. Ahmäe; E. Heinaste; K. Vabrit; V. Tammekivi; E. Hallast; K. Koido; A. Kurg; J. Shlik; V. Vasar; A. Metspalu; E. Vasar (S55-S56).
P.3.04 Sumatriptan effect on regional brainperfusion: predicting therapeutic response in OCD by E. Harary; T. Hendler; J. Zohar; M. Lustig; E. Goshen; T.S. Zwas; Y. Sasson (S55).
P.3.03 Poststroke depression — diagnosis and treatment by G. Djokic; N. Zivkovic; A. Dostanie; S. Milivojevic (S54-S55).
P.3.08 Quantification of serotonin transporterswith [123I]ADAM and SPECT in healthy human subjects: preliminary data on tracer kinetics by J. Sacher; N. Klein; T. Geiss-Granadia; N. Mossaheb; T. Attarbaschi; A. Holik; S. Asenbaum; C. Pötzi; G. Dobrozemsky; R. Dudczak; S. Kasper; J. Tauscher (S58).
P.3.09 Comparison of bone metabolism between patients with restrictive and bulimic type of anorexia nervosa by A. Śmiech; J. Rabe-Jabłońska (S58-S59).
P.3.13 Clinical impact of CYP2D6 polymorphismin patients with Alzheimer's disease in therapy with donepezil by M.G. Scordo; E. Varsaldi; G. Miglio; M.L. Villa; A. Biolcati; M.-L. Dahl; G. Lombardie (S61-S62).
P.3.12 Recovery from bipolar depression aftertotal sleep deprivation: a 3.0 T BOLD fMRl event-related study of moral thinking by A. Bernasconi; D. Radaelli; F. Benedetti; V. Blasi; M. Cadioli; C. Colombo; A. Falini; G. Scotti; E. Smeraldi (S61).
P.3.11 Intravenous infusion of allopregnanoloneinduces sedation in humans by F. Van Broekhoven; T. Bäckström; I. Sundström; E.L. van Luijtelaar; E. Smits; R.J. Verkes (S60).
P.3.10 Ethanol-like effects of N-methyl-d-aspartatereceptors antagonist memantine, and its ability to prevent cue induced alcohol craving by M. Tsoy; E.M. Krupitsky; O.N. Neznanova; A.M. Burakov; T.Y. Didenko; D.V. Masalov; T.N. Romanova; A.Y. Bespalov; E.E. Zvartau; J. Krystal (S59-S60).
P.3.02 The time course of neuropsychiatric symptoms induced by pegylated interferon-alpha-2b and ribavirin treatment for hepatitis C: a follow-up study by S.J.H. Bull; C. Maddock; S. Landau; K. Barry; P. Maulayah; M. Hotopf; A. Cleare; S. Norris; C. Pariante (S53-S54).
P.3.01 Neurocognitive impairment in euthymic young adults with recurrent depression: a case-control comparison of major depression and bipolar-spectrum disorder by D.J. Smith; W.J. Muir; D.H.R. Blackwood (S52-S53).
P.2.20 c-fos mRNA expression within the ratbrain after exposure to the elevated plus maze: effect of prior treatment with anxiogenic and anxiolytic drugs by C. Troakes; C.D. Ingram (S46-S47).
P.2.21 Behavioural investigation into the role of corticotropin releasing factor in the frontal cortex of rat brain by B. Zieba; J.M. Wieronska; M. Smialowska; H. Domin; A. Pile (S47).
P.2.19 GABAB receptor positive modulation as a novel therapeutic approach to drug dependence: blockade of the rewarding and psychostimulant effects of cocaine by D.A. Slattery; C. Mombereau; W. Froestl; A. Markou; K. Kaupmann; J.F. Cryan (S45-S46).
P.2.18 Altered physiological responses to stress in the olfactory bulbectomised rat: normalisation by chronic fl uoxetine treatment by M. Roche; A. Harkin; J.P. Kelly (S44-S45).
P.2.17 Endocrine and immune changesfollowing chronic treatment with tiagabine and amisulpride in the olfactory bulbectomized rat model of depression by J. Pistovcakova; A. Makatsori; M. Dostalek; A. Sulcova; D. Jezova (S44).
P.2.22 Strain related gender differences incortical 5-HT autoreceptor responses to sub-chronic fluoxetine by G. Shalom; T. Lifshytz; E. Gur; B. Lerer; M.E. Newman (S47-S48).
P.2.23 Evidence for social recognition inC57BL/6J and A/J mice by A.A. Malyshkin; E.E. Zvartau; J.M. Van Ree; M.J.H. Kas (S48-S49).
S.3.2 Endophenotypes for affective disorders by S. Modell (S51-S52).
S.3.1 Clinical neuropsychopharmacology: focuson depression imaging in clinical research by H.S. Mayberg (S51).
P.2.25 Characterisation of a caffeine-inducedmodel of insomnia in the rat by L.M. Paterson; M. Ivarsson; P.H. Hutson (S49-S50).
P.2.24 Naloxone administration partially prevents ethanol effects on the sleep-wakefulness cycle in rats by T. Basishvili; M. Gogichadze; I. Rukhadze; N. Emukhvari (S49).
P.3.14 Cholinergic modulation of memory, learning and visuospatial processes in healthy elderly volunteers by E. Wezenberg; R.J. Verkes; B.G.C. Sabbe; G.S.E Ruigt; W. Hulstijn (S62-S63).
P.3.15 Neural correlates of distorted moralthinking in bipolar depression: a 3.0 T BOLD fMRl event-related study by D. Radaelli; A. Bernasconi; E. Benedetti; V. Blasi; M. Cadioli; C. Colombo; A. Falini; G. Scotti; E. Smeraldi (S63).
P.4.06 Behavioral modifications induced by dietary cholesterol in rats by V. Micale; C. Mazzola; G.M. Leggio; D.L. Alkon; F. Drago (S76).
P.4.07 Potential antidepressant-like effect of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP), a potent and highly selective mGIuR5 antagonist by A. Palucha; P. Branski; B. Szewczyk; J.M. Wieronska; A. Pile (S77).
P.4.05 Morphologic changes of heart electric field in depressive patients treated with dosulepine by E. Kitzlerová; O. Kittnar; I. Paclt; J. Slavíček; M. Anders; A. Dohnalová (S75-S76).
P.4.04 Substitution of venlafaxine by fluoxetine and tianeptine in a conditioned taste aversion paradigm by H. Kayir; T. Alici; I.T. Uzbay (S74-S75).
P.4.03 Effect of the combinations of weak-opiate analgesics with antidepressants in the tail suspension test by E. Berrocoso; J.A. Micó (S74).
P.4.08 Neurophysins response to apomorphineand clonidine in major depression by G. Scantamburlo; M. Hansenne; M. Ansseau; J.J. Legros (S77-S78).
P.4.09 Behavioural and neurochemical consequencesof sIRNA-induced knockdown of serotonin and dopamine transporters in the adult mouse brain: Implications for validation of novel antidepressant targets by D.R. Thakker; F. Natte; D. Hüsken; R. Maier; H. van der Putten; D. Hoyer; J.F. Cryan (S78-S79).
Keyword index (S85-S86).
Author index (S81-S83).
P.4.11 Activation of brain indoleamine 2,3-dioxygenase (IDO) by cytokines: a model of depressive disorders? by M. Moreau; N. Castanon; J. Lestage (S80).
P.4.10 Different response to a dexamethasone and prednisolone test in treatment-resistant depressed patients by M.F. Juruena; A. Cleare; A.S. Papadopoulos; L. Poon; S. Lightman; C.M. Pariante (S79-S80).
P.4.02 Functional genomics-based identificationand validation of therapeutic targets and molecular markers for treatment and diagnosis of Major Depression by D. Arteta; E. Entrena; A. Martínez; L.E. Callado; J.J. Meana (S73).
P.4.01 A functional NOS-III haplotype is associated with bipolar disorder by A. Reif; A. Strobel; C.P. Jacob; S. Fritzen; A. Schmitt; K.-P. Lesch (S72-S73).
P.3.19 Quantification of striatal D2 receptoroccupancy in bipolar patients treated with olanzapine using [123I] lodobenzamide and SPECT by T. Attarbaschi; T. Geiss-Granadia; J. Sacher; N. Klein; N. Mossaheb; G. Wiesegger; R. Lanzenberger; S. Asenbaum; R. Dudczak; S. Kasper; J. Tauscher (S66).
P.3.20 An fMRI study of the effect ofmethylphenidate on neurocognitive function in children with ADHD by R. Halari; E. Taylor; A. Smith; M. Mohammad; M. Brammer; K. Rubia (S66-S67).
P.3.18 Early course of schizophrenic disorders;results from a Dutch epidemiological study by N. Veen; R.S. Kahn; H.W. Hoek; W. Laan; D.S. Schols; I. van der Tweel; J.P. Selten (S65-S66).
P.3.17 Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the ÆSOP study by P. Dazzan; K.D. Morgan; K. Orr; G. Hutchinson; X. Chitnis; J. Suckling; P. Fearon; P.K. McGuire; R.M. Mallett; P.B. Jones; J. Leff; R.M. Murray (S64-S65).
P.3.16 Dopaminergic modulation of processing of uncertainty: a fMRl challenge study with methylphenidate by I. Nenadic; R. Schlösser; S. Zysset; K. Volz; S. Köhler; U. Demme; R. Schubotz; H. Sauer; D.Y. von Cramon (S64).
P.3.21 The effect of clozapine on factorscontrolling glucose homeostasis by O.D. Howes; A. Bhatnagar; E.P. Gaughran; S. Amiel; R.M. Murray; L.S. Pilowsky (S67-S68).
P.3.22 Predictive factors of resistance to antidepressant treatment: results from a European multicentre study by P. Oswald; D. Souery; S. Kaspere; Y. Lecrubier; J. Zohar; J. Mendlewicz (S68-S69).
S.4.2 Bipolar disorder by G.M. Goodwin; W.A. Handley (S71-S72).
S.4.1 Neurotrophins and antidepressant drugaction by E. Castrén (S71).
P.3.24 Volumes of brain structures in twinsdiscordant for bipolar disorder by A.C. van der Schot; R. Vonk; H.E. Hulshoff Pol; V. Nuboer; W. Nolen; R.S. Kahn (S69-S70).
P.3.23 Naltrexone for treatment of heroindependence in Russia by V. Egorova; E.M. Krupitsky; E.E. Zvartau; D.V. Masalov; M.V. Tsoi; A.M. Burakov; T.Y Didenko; T.N. Romanova; E.B. Ivanova; A.Y. Bespalov; E. Verbitskaya; N.G. Neznanov; A.Y. Grinenko; G. Woody (S69).
P.2.16 Noradrenergic facilitation of shock-probe defensive burying in lateral septum by C.O. Petre; G. Barrera; D.A. Morilak (S43).
P.2.15 Kynurenic acid andN-acetylaspartylglutamate do not alter PPI in mice by E. Pålsson; D. Klamer; A. Revesz; J.A. Engel; L. Svensson (S42-S43).
P.1.16 Novelty induces phosphorylation and phospho-acetylation of histone H3 in rat dentate gyrus granule neurons by Y. Chandramohan; S.K. Droste; J.M.H.M. Reul (S14-S15).
P.1.17 Regulation of synaptic transmission inthe striatum by protein kinases by K. Chergui (S15-S16).
P.1.15 Differential alterations in GABAA receptorexpression and function induced by ethanol of hippocampal and cerebellar granule cells by M. Carta; M.L. Mura; M.C. Mostallino; S. Caria; G. Gorini; E. Biggio; P. Follesa; G. Talani; E. Busonero; E. Sanna; G. Biggio (S14).
P.1.14 Modulation of the mesocortical dopaminergic system by prefrontal 5-HT1A receptors. Role in antipsychotic drug action by A. Bortolozzi; M.C. Scorza; L. Díaz-Mataix; E. Celada; M. Toth; F. Artigas (S13-S14).
P.1.13 Hyperactivity and altered dopaminergicfunction in FGF-2 knockout mice by E. Bedogni; P. Fadda; A. Fresu; G. Racagni; M.A. Riva (S12-S13).
P.1.18 Serotonin receptors expression in glutamatergic and GABAergic cells in human and monkey prefrontal cortex by J. de Almeida (S16).
P.1.19 The role of brain derived neurotropic factor (BDNF) in anorexia nervosa and hyperactivity by M. de Krom; J. Hillebrand; J. Hendriks; A. van Elburg; R. Adan (S16-S17).
P.1.23 The long-term paraquat administration produces a slowly progressing degeneration of the nigrostriatal system in rats by K. Kuter; J. Wardas; E. Nowak; J. Dąbrowska; A. Bortel; L. Labus; T. Lenda; M. Šmialowska; J. Wierońska; B. Ziéba; S. Wolfarth; K. Ossowska (S20).
P.1.22 Proteomic search for intracellular bindingsites of antidepressants by T. Kirmeier; C. Turck; E. Holsboer; T. Rein (S19).
P.1.21 Chronic antidepressant treatments reduce glutamate release and protein-protein interactions favoring formation of snare complex by M. Popoli; R. Giambelli; L. Raiteri; E. Tiraboschi; L. Musazzi; V. Barbiero; M. Raiteri; G. Racagni; G. Bonanno (S18-S19).
P.1.20 Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by exogenous 5-HT1A receptor activation by L. Díaz-Mataix; P. Celada; F. Artigas (S17-S18).
P.1.12 MAO-A genotype interaction with environment (psychosocial factors) and risk for criminality and alcohol related problems by H. Wargelius; K. Nilsson; R. Sjoberg; L. Oreland (S12).
P.1.11 Hyperforin inhibits serotonin uptake by activating non selective cation channels by K. Treiber; A. Singer; B. Henke; W.E. Müller (S11-S12).
P.1.03 N-terminal domain of Wolframin interactswith carboxypeptidase E by H. Luuk; U. Tools; S. Kôks; E. Vasar (S5-S6).
P.1.04 Impacts of type I interferons (IFN-α andIFN-τ) and type II interferon (IFN-γ) on the kynurenine pathway in human uninfected or HIV-1 infected macrophages by B. Manéglier; C. Rogez-Kreuz; O. Spreux-Varoquaux; N. Dereuddre-Bosquet; J. Marlal; P. Thérond; C. Advenier; D. Dormont; P. Clayette (S6).
P.1.02 The effect of chronic lithium and lithium withdrawal on ventral tegmental area dopaminergic function by L.J. Ferrie; C.M. Martin; A.H. Young; S.E. Gartside; R. McQuade (S4-S5).
P.1.01 Schizophrenia-associated-proteins ina neurodevelopmentally rat model of schizophrenia by N. Carmit; B.K. Lipska; R.H. Belmaker; G. Agam (S3-S4).
S.1.2 Molecular concepts: histone modificationsto investigate the impact of stress on the brain by J.M.H.M. Reul; S.K. Droste; Y. Chandramohan (S2-S3).
P.1.05 Benzodiazepine-adrenergic receptorinteractions in the pathophysiology of major depression by S. Minenko (S6-S7).
P.1.06 Chronic lithium treatment attenuatesmarkers of ageing in the hippocampus of C57BL/6 mice by A. Shaldubina; S. Shoham; Y. Bersudsky; R.H. Belmaker; G. Agam (S8).
P.1.10 Effect of St. John's wort (Hypericumperforatum) on cytochrome P-450 2C6, 2D2 and 3A1/2 in rats by M. Dostalek; J. Pistovcakova; J. Jurica; J. Tomandl; I. Linhart; A. Sulcová; E. Hadasova (S10-S11).
P.1.09 Stabilization of mitochondrial function bystandardized Ginkgo biloba extract by U. Keil; A. Eckert; W.E. Müller (S10).
P.1.08 Effect of fluoxetine on GABA(B) receptorexpression and function in the dorsal horn of the rat spinal cord by I. Korzh; I.F. Fedotova; V.D. Nemtsova (S9).
P.1.07 Glutamatergic aspects of psychosis in neurodevelopmental animal model: What can they teach us about schizophrenia? by I. Skuba; E. Št'astý (S8-S9).
P.1.24 A transmembrane calcium flux is requiredfor circadian clock gene rhythmicity in mammalian pacemaker neurons by G. Lundkvist; Y. Kwak; E. Davis; H. Tei; G. Block (S20-S21).
P.1.25 Galantamine increases firing activity of dopaminergic neurons in the ventral tegmental area by B. Schilström; V. Ivanov; C. Wiker; T.H. Svensson (S21-S22).
P.2.07 Selecting over-active extremes in outbred heterogeneous stock (HS) mice for gene expression profiling: nominating novel candidate genes for over-activity by L. Liu; C. Fernandes; K. Brookes; J. Paya-Capo; P. Asherson; L.C. Schalkwyk (S36-S37).
P.2.08 Role of the cannabinoid cb1 receptorantagonist sr 141716a in relapse to heroin seeking by L. Fattore; G. Cossu; M.S. Spano; S. Deiana; P. Fadda; W. Fratta (S37).
P.2.06 Central activation of corticotropin-releasing factor receptor type 1 and type 2 receptors results in distinct serotonergic, neuroendocrine and behavioural responses by L. de Groote; C. Flachskamm; R.G. Peñalva; J.M.H.M. Reul; A.C.E. Linthorst (S35-S36).
P.2.05. Rats reared in social isolation displaydisrupted ppi and elevated levels of kynurenic acid in the hippocampus by S. Erhardt; S.B. Powell; L.K. Nilsson; K.R. Linderholm; N.R. Swerdlow; M.A. Geyer (S34-S35).
P.2.04 The role of the melanocortin sytem in visceral pain by G.J. Geerse; V.M. Wiegant; R. Stam (S34).
P.2.09 The paracapsular cells of the amgydala: an inhibitory network under dopaminergic control by A. Marowsky; H. Möhler; K.E. Vogt (S38).
P.2.10 Discriminative stimulus propertiesof tianeptine: partial substitution by fluoxetine and 8-OH-DPAT by T. Alici; H. Kayir; M.O. Aygoren; E. Saglam; I.T. Uzbay (S38-S39).
P.2.14 Influence of NMDA-receptors blockator on the sleep-wakefulness cycle in cats by O. Mchedlidze; N. Menteshashvili; M. Gogichadze; N. Lortkipanidze; E. Chidjavadze; L. Beritashvili (S41-S42).
P.2.13 D3 dopamine receptor knockout mice: behavioral alteration in experimental models of anxiety by G.M. Leggio; C. Mazzola; V. Micale; D. Consoli; T. Incognito; E. Drago (S41).
P.2.12 Pharmacological validation of the mouse elevated horizontal rod (the Suok test) as a novel experimental model of anxiety: sensitivity to diazepam and pentylenetetrazole by A.V. Kalueff; P. Tuohimaa (S40-S41).
P.2.11 Crossbreeding studies with helpless “HIRouen” and “NH/Rouen” indicate that some phenotypic differences between the lines are related to the helpless trait by M. El Yacoubi; D. Popa; B. Martin; M. Hamon; J. Costentin; J. Adrien; J.-M. Vaugeois (S39-S40).
P.2.03 Effect of urocortin 2 on home cagebehaviors and serotonergic neurons in the dorsal raphe nucleus by D.R. Staub; E. Spiga; C.A. Lowry (S33-S34).
P.2.02 The 5-HT1A and GABAA-benzodiazepine receptors: Effects in behavior and pharmacology in female 5-HT1A knockout mice by M.J.V. Van Bogaert; L. Gerritsen; L. Groenink; R.S. Oosting; B. Olivier (S32-S33).
P.1.29 Subtype dependent changes of α1-adrenoceptormRNAs expression in the rat prefrontal cortex induced by the chronic mild stress procedure by A. Bielawski; A. Zelek-Molik; M. Papp; I. Nalepa (S24-S25).
P.1.30 Proteins involved in the cell death induced by a fragment of APP by A. Madeira; J.M. Pommet; F. Parker; M. Duchenne; L. Mercken; L. Pradier; A. Prochiantz; B. Allinquant (S25).
P.1.28 Excitatory effects of thyrotropin-releasing hormone (TRH) in the thalamus: evidence for a role in the switch between sleep and waking by C. Broberger (S23-S24).
P.1.27 An endogenous compound 1-methyl-1,2,3,4-tetrahydroisoquinolineprevents the morphine addiction in rat: the view on neurochemical mechanism of action by A. Wąsik; A. Patsenka; L. Antkiewicz-Michaluk (S22-S23).
P.1.26 Identification of stress-regulated genes in the brain of two mouse strains that differ in the antidepressant responsiveness by A. Tsolakidou; M. Panhuysen; I. Sillaber; B. Puetz; F. Holsboer; T. Rein (S22).
P.1.31 Constitutive dimerization of the histamineH3 receptor in living cells by S. Morisset; C. Chabret; J.M. Arrang (S25-S26).
P.1.32 Association between the serotonin transporter linked polymorphic region gene and response to tricyclic antidepressants by E. Tsapakis; S. Checkley; R.W Kerwin; K.J. Aitchison (S26-S27).
P.2.01 The effects of altering dietary L-tryptophan on the performance of an iterated Prisoner's Dilemma (PD) game in healthy volunteers by R.M. Wood; J.K. Rilling; A.G. Sanfey; Z. Bhagwagar; R.D. Rogers (S32).
S.2.2 Neuropsychopharmacology: bridginganimal and human studies by P. Blier (S30-S31).
S.2.1 Behavioral correlates of neurotransmitterfunction in depression by F. Artigas (S29-S30).
P.1.33 5-HT1A receptor activation inducesupregulation of GABAAR gene expression in neurones by Z. Zhang; D.J. Nutt; S.J. Bailey (S27).
S.1.1 Genetic approaches to psychiatricdiseases by D. Goldman (S1-S2).